Tracking T-cell immune reconstitution after TCRαβ/CD19-depleted hematopoietic cells transplantation in children

被引:0
作者
I V Zvyagin
I Z Mamedov
O V Tatarinova
E A Komech
E E Kurnikova
E V Boyakova
V Brilliantova
L N Shelikhova
D N Balashov
M Shugay
A L Sycheva
S A Kasatskaya
Y B Lebedev
A A Maschan
M A Maschan
D M Chudakov
机构
[1] Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry,
[2] Russian Academy of Science,undefined
[3] CEITEC MU,undefined
[4] Masaryk University,undefined
[5] Dmitrii Rogachev Federal Research Center for Pediatric Hematology,undefined
[6] Oncology and Immunology,undefined
[7] Pirogov Russian National Research Medical University,undefined
来源
Leukemia | 2017年 / 31卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
αβT-cell-depleted allogeneic hematopoietic cell transplantation holds promise for the safe and accessible therapy of both malignant and non-malignant blood disorders. Here we employed molecular barcoding normalized T-cell receptor (TCR) profiling to quantitatively track T-cell immune reconstitution after TCRαβ-/CD19-depleted transplantation in children. We demonstrate that seemingly early reconstitution of αβT-cell counts 2 months after transplantation is based on only several hundred rapidly expanded clones originating from non-depleted graft cells. In further months, frequency of these hyperexpanded clones declines, and after 1 year the observed T-cell counts and TCRβ diversity are mostly provided by the newly produced T cells. We also demonstrate that high TCRβ diversity at day 60 observed for some of the patients is determined by recipient T cells and intrathymic progenitors that survived conditioning regimen. Our results indicate that further efforts on optimization of TCRαβ-/CD19-depleted transplantation protocols should be directed toward providing more efficient T-cell defense in the first months after transplantation.
引用
收藏
页码:1145 / 1153
页数:8
相关论文
共 328 条
[1]  
Copelan EA(2006)Hematopoietic stem-cell transplantation N Engl J Med 354 1813-1826
[2]  
Szydlo R(1997)Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings J Clin Oncol 15 1767-1777
[3]  
Goldman JM(2001)The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation Blood 98 3192-3204
[4]  
Klein JP(1998)Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype N Engl J Med 339 1186-1193
[5]  
Gale RP(1998)T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease Blood 91 1083-1090
[6]  
Ash RC(1999)Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions Blood 93 467-480
[7]  
Bach FH(2000)T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities Blood 95 3996-4003
[8]  
Ho VT(2012)Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation Biol Blood Marrow Transplant 18 1835-1844
[9]  
Soiffer RJ(2014)T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor Bone Marrow Transplant 49 999-1008
[10]  
Aversa F(2013)Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device Cytotherapy 15 1253-1258